FDA Restrictions on Mifepristone: Time for a Change?

التفاصيل البيبلوغرافية
العنوان: FDA Restrictions on Mifepristone: Time for a Change?
المؤلفون: Weiner, Janet, Schreiber, Courtney A.
المصدر: 147 ; 1 ; Issue Briefs ; published ; 24
سنة النشر: 2020
المجموعة: University of Pennsylvania: ScholaryCommons@Penn
مصطلحات موضوعية: miscarriage, mifepristone, fda, pregnancy, pregnant, trimester, Health Economics, Health Policy, Maternal and Child Health, Obstetrics and Gynecology, Women's Health
الوصف: Mifepristone, a drug used to manage early miscarriage or end an early pregnancy, carries unique restrictions imposed by the U.S. Food and Drug Administration (FDA). Patients are required to pick up the drug in person from a doctor or a clinic, even though they can take the drug at home. In July, a federal court ruled that the FDA must suspend these restrictions during the COVID-19 pandemic, for patients seeking an early abortion, although the ruling did not apply to women with an early pregnancy loss. But the challenges to FDA restrictions on mifepristone predate the pandemic. This Issue Brief provides the context for this ongoing controversy, and reviews recent evidence on the clinical and cost effectiveness of mifepristone for the medical management of first trimester miscarriage.
نوع الوثيقة: manuscript
وصف الملف: application/pdf
اللغة: unknown
العلاقة: https://ldi.upenn.edu/brief/fda-restrictions-mifepristone-time-changeTest; https://repository.upenn.edu/handle/20.500.14332/38126Test
الإتاحة: https://doi.org/20.500.14332/38126Test
https://repository.upenn.edu/handle/20.500.14332/38126Test
https://hdl.handle.net/20.500.14332/38126Test
حقوق: http://creativecommons.org/licenses/by-nd/4.0Test/
رقم الانضمام: edsbas.F68C7EE4
قاعدة البيانات: BASE